ALS News | ALS Therapy Development Institute

Your support fuels our research to #EndALS!

Donate Now

ALS Research News

Wednesday, December 29, 2021

Proudly Reflecting on ALS Research in 2020

A letter from the ALS Therapy Development Institute's (ALS TDI) Chief Scientific Officer, Fernando Vieira M.D.

Friday, January 15, 2021

4 Things to Look for in ALS Research in 2021

Looking forward to the most exciting trends in ALS research in the new year.

Tuesday, December 8, 2020

2020 ALS TDI Summit Highlights Progress and Collaboration in a Challenging Year

2020 was a year unlike any other, and so was this years's ALS TDI Summit.

From trial readouts to news from our lab, you can find all of the latest ALS research news here.

More ALS Research News

COVID-19 Updates

Tuesday, June 2, 2020

How ALS TDI is Moving Forward with Phase 1 Reopening of Lab

Friday, May 29, 2020

ALS TDI Researchers Keep Essential Animal Experiments Running in the Lab

Monday, May 11, 2020

My-State Trek: How Team America Captain Rinaldo Dorman is Getting Ready for the Virtual Ride to Support ALS TDI

More COVID-19 Updates

ALS TDI Community Blog

Friday, December 31, 2021

We Will Continue to Work for You

A letter from the ALS Therapy Development Institute's (ALS TDI) Chief Executive Officer, Dr. Steve Perrin.

Friday, February 26, 2021

Why ALS is more like a Syndrome than a Disease, and what that Means for Treatments

There are a lot of different names for ALS – amyotrophic lateral sclerosis, Lou Gehrig’s

Friday, February 12, 2021

What is Bulbar Onset ALS?

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's Disease, is a diverse syndrome...

Blog posts and commentary pieces from ALS TDI and community members with topics ranging from funding ALS research to how ALS impacts the lives of community members.

ALS TDI Press Releases

Monday, November 2, 2020

Novus Therapeutics Announces Enrollment of First ALS Patient in Phase 2 Trials of AT-1501, A Drug Invented at ALS-TDI

The ALS Therapy Development Institute (ALS TDI) is excited to share a significant step in the advancement of AT-1501

Monday, September 14, 2020

Acquisition of Anelixis Therapeutics Fuels Hopes of AT-1501 Push to Phase 2 Clinical Trials

The ALS Therapy Development Institute (ALS TDI) is excited to share that Anelixis Therapeutics, the

Monday, April 27, 2020

Giving Tuesday Now with ALS TDI

#GivingTuesdayNow is scheduled to take place Tuesday, May 5, 2020.

A complete list of press releases from the ALS Therapy Development Institute.

More ALS TDI Press Releases

Learn more about our team, what what we're working on in the lab, and our amazing community by following us on social media!

Media Contact

We'd love to share our story with you. Speak to our team about our unique approach to end ALS.

marketing@als.net | 617.441.7200

ALS News & Stories